Baseline Characteristics and Response to 2 Years of Growth Hormone (GH) Replacement of Hypopituitary Patients with GH Deficiency due to Adult-Onset Craniopharyngioma in Comparison with Patients with Nonfunctioning Pituitary Adenoma: Data from KIMS (Pfizer International Metabolic Database)
Objective: In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitar...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 90; no. 8; pp. 4636 - 4643 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bethesda, MD
Oxford University Press
01.08.2005
Endocrine Society |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-972X 1945-7197 |
| DOI | 10.1210/jc.2005-0185 |
Cover
| Abstract | Objective: In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement.
Patients: Baseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients.
Results: At baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m2; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy.
Conclusions: In the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time. |
|---|---|
| AbstractList | In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement.OBJECTIVEIn epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement.Baseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients.PATIENTSBaseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients.At baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m2; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy.RESULTSAt baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m2; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy.In the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time.CONCLUSIONSIn the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time. Objective: In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement. Patients: Baseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients. Results: At baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m2; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy. Conclusions: In the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time. Objective: In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement. Patients: Baseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients. Results: At baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m2; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy. Conclusions: In the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time. In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a craniopharyngioma (CP) and/or its treatment have a higher mortality than patients with other etiologies, such as a nonfunctioning pituitary adenoma (NFPA). To analyze this difference, we used the KIMS database (Pfizer International Metabolic Database) comparing CP and NFPA patients in terms of baseline characteristics and responses to GH replacement. Baseline characteristics were studied in 351 CP patients (189 men and 162 women; mean age, 42.5 yr) and compared with 370 NFPA patients, matched for age and sex (185 men and 185 women; mean age, 42.5 yr). The effects of 2 yr of GH replacement were analyzed in a subgroup of 183 CP and 209 NFPA patients. At baseline, both CP and NFPA patients had characteristic features of GH deficiency, with low serum IGF-I, increased body fat, dyslipidemia, and reduced quality of life. Male CP patients were significantly more obese (30.0 vs. 28.2 kg/m2; P = 0.0003) compared with NFPA patients, had a higher waist/hip ratio (P = 0.004), higher triglycerides (P = 0.003), and lower high-density lipoprotein cholesterol (P = 0.03). Similar, but much smaller, differences were seen in female CP compared with NFPA patients, only reaching significance for waist/hip ratio (P = 0.05) and triglycerides (P = 0.0004). CP patients had more often undergone surgery by the transcranial route (68.8% vs. 30.9%; P < 0.0001), and panhypopituitarism was more prevalent in CP than in NFPA patients (58.7% vs. 19.8%; P < 0.0001). The incidence of previous fractures, hypertension, coronary heart disease, claudication, and diabetes mellitus was high, but not different, between CP and NFPA patients. After 2 yr of GH replacement therapy, similar significant improvements were evident in both groups in fat-free mass, total and low-density lipoprotein cholesterol, and Quality-of-Life-Assessment in GH Deficient Adults score compared with baseline. In contrast to NFPA patients, CP patients had no significant decrease in body fat with GH therapy. In the KIMS database, patients with CP have more often undergone surgery by the transcranial route than patients with NFPA, have a higher prevalence of pituitary deficiencies, are more obese (predominantly males), and have more dyslipidemia. This could provide an explanation, at least in part, for the higher mortality rate in CP patients observed in epidemiological studies. CP patients respond equally well to GH therapy in fat-free mass, lipids, and quality of life, but are less likely to lose body fat. We assume that this difference in response merely reflects the stronger tendency of CP patients to accumulate fat over time. |
| Author | Kendall-Taylor, Pat Geffner, Mitchell Koltowska-Häggström, Maria Jönsson, Peter J. Verhelst, Johan Abs, Roger Erfurth, Eva Marie Wilton, Patrick Price, David Anthony |
| Author_xml | – sequence: 1 givenname: Johan surname: Verhelst fullname: Verhelst, Johan email: johan.verhelst@zna.be organization: 1General Hospital Middelheim (J.V.), B-2020 Antwerp, Belgium – sequence: 2 givenname: Pat surname: Kendall-Taylor fullname: Kendall-Taylor, Pat organization: 2University of Newcastle (P.K.-T.), Newcastle upon Tyne NE2 4HH, United Kingdom – sequence: 3 givenname: Eva Marie surname: Erfurth fullname: Erfurth, Eva Marie organization: 3University Hospital (E.M.E.), S-221 85 Lund, Sweden – sequence: 4 givenname: David Anthony surname: Price fullname: Price, David Anthony organization: 4Royal Manchester Children’s Hospital (D.A.P.), Manchester M27 4HA, United Kingdom – sequence: 5 givenname: Mitchell surname: Geffner fullname: Geffner, Mitchell organization: 5Saban Research Institute of Childrens Hospital (M.G.), Los Angeles, California 90027 – sequence: 6 givenname: Maria surname: Koltowska-Häggström fullname: Koltowska-Häggström, Maria organization: 6KIGS/KIMS Outcomes Research, Endocrine Care, Pfizer (M.K.-H., P.J.J., P.W.), SE-112 87 Stockholm, Sweden; and University Hospital (R.A.), B-2650 Edegem, Belgium – sequence: 7 givenname: Peter J. surname: Jönsson fullname: Jönsson, Peter J. organization: 6KIGS/KIMS Outcomes Research, Endocrine Care, Pfizer (M.K.-H., P.J.J., P.W.), SE-112 87 Stockholm, Sweden; and University Hospital (R.A.), B-2650 Edegem, Belgium – sequence: 8 givenname: Patrick surname: Wilton fullname: Wilton, Patrick organization: 6KIGS/KIMS Outcomes Research, Endocrine Care, Pfizer (M.K.-H., P.J.J., P.W.), SE-112 87 Stockholm, Sweden; and University Hospital (R.A.), B-2650 Edegem, Belgium – sequence: 9 givenname: Roger surname: Abs fullname: Abs, Roger organization: 1General Hospital Middelheim (J.V.), B-2020 Antwerp, Belgium |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17004765$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15928246$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-74031$$DView record from Swedish Publication Index |
| BookMark | eNp1k1tv1DAQhQMqohd44xkZIaAVpNjOnbdlF3YrWlpxEzxZs86k9Sqxg-1otfx6vN3Sikp9iuR8c2bG53g32tJGYxQ9YfSQcUbfLuQhpzSLKSuz-9EOq9IsLlhVbEU7lHIWVwX_uR3tOreglKVpljyMtllW8ZKn-c69Z-_BYas0kvEFWJAerXJeSUdA1-QLut5oh8QbwskvBOuIacjUmqW_IDNjuzAL2Z_ODgLatyCxQ-3XyGzVm175QXmwK3IGXoUfjixVqJvOyAQbJcORXJF6uJQf1UPr49PQzJOxBa1MHwZa6XNlOiBKk7HpegjDGb1R-V_zs9HNoKVXRit9Ts6uW49q1EHhHZmAB9JY05FPRydfyf5Zo_6gJUc6rKxhXQgtOUEPc9MqeYnPw90cPIoeNNA6fHz13Yu-f_zwbTyLj0-nR-PRcSxTlvk4T5OackyyHMqK8YaVLCnyVGbzJpEZR9kEl0qYS85TgIzXNKcNIs05x6IuIdmLXm903RL7YS56q7qwgDCgxET9GAljz8UwiCKlCQv0yw3dW_N7QOdFp5zEtgWNZnAiL9Oc0SoP4PNb4MIMYeHWiYTlSV6ltCwD9fSKGuYd1tfN_wUlAC-uAHAS2iY4JJW74QpK0yLPAvdmw0lrnLPY3CBUrPMqFlKs8yrWeQ04v4XLYNvaDG9BtXcVvdoUmaG_S_7yOSR_AXF-_SA |
| CODEN | JCEMAZ |
| CitedBy_id | crossref_primary_10_1227_01_NEU_0000372918_68453_5B crossref_primary_10_1210_jc_2009_2506 crossref_primary_10_1111_j_1365_2265_2011_04137_x crossref_primary_10_6065_apem_2346206_103 crossref_primary_10_1016_j_ando_2007_04_001 crossref_primary_10_1210_jc_2018_02608 crossref_primary_10_1210_clinem_dgaa985 crossref_primary_10_1007_s12020_017_1489_9 crossref_primary_10_1111_cen_13929 crossref_primary_10_1530_EJE_13_0280 crossref_primary_10_1016_S0084_3741_08_70466_9 crossref_primary_10_1007_s40618_014_0196_0 crossref_primary_10_1530_EJE_12_0002 crossref_primary_10_1097_CRD_0b013e318248a3e1 crossref_primary_10_1530_EJE_15_0305 crossref_primary_10_1007_s11102_017_0860_4 crossref_primary_10_1007_s40618_013_0050_9 crossref_primary_10_1016_j_endonu_2012_11_008 crossref_primary_10_1530_EJE_09_0273 crossref_primary_10_1007_s11102_011_0349_5 crossref_primary_10_14341_probl201157239_45 crossref_primary_10_1016_j_ghir_2007_05_005 crossref_primary_10_1007_s11102_015_0636_7 crossref_primary_10_2147_DMSO_S425399 crossref_primary_10_1016_j_ando_2024_07_002 crossref_primary_10_1002_pds_1510 crossref_primary_10_1111_j_1365_2265_2006_02508_x crossref_primary_10_1530_EJE_09_0258 crossref_primary_10_1111_j_1365_2265_2010_03838_x crossref_primary_10_1159_000499430 crossref_primary_10_1016_j_beem_2017_03_001 crossref_primary_10_1016_j_ghir_2014_07_002 crossref_primary_10_1097_01_med_0000202323_44809_4f crossref_primary_10_1038_nrendo_2016_84 crossref_primary_10_4158_EP_2018_0154 crossref_primary_10_1111_cen_13030 crossref_primary_10_1530_EJE_09_0291 crossref_primary_10_1186_s12885_024_13352_w crossref_primary_10_1016_j_beem_2023_101821 crossref_primary_10_1007_s11102_008_0096_4 crossref_primary_10_1530_EJE_09_0266 crossref_primary_10_1016_j_ecl_2007_10_012 crossref_primary_10_1007_s11102_012_0428_2 crossref_primary_10_1111_j_1365_2265_2011_03993_x crossref_primary_10_1007_s11102_024_01488_8 crossref_primary_10_1530_EJE_12_0077 crossref_primary_10_1016_j_endoen_2012_11_010 crossref_primary_10_1111_joim_13382 crossref_primary_10_1007_s11102_022_01207_1 |
| ContentType | Journal Article |
| Copyright | Copyright © 2005 by The Endocrine Society 2005 2005 INIST-CNRS Copyright © 2005 by The Endocrine Society |
| Copyright_xml | – notice: Copyright © 2005 by The Endocrine Society 2005 – notice: 2005 INIST-CNRS – notice: Copyright © 2005 by The Endocrine Society |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 ADTPV AOWAS DF2 |
| DOI | 10.1210/jc.2005-0185 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic SwePub SwePub Articles SWEPUB Uppsala universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | 4643 |
| ExternalDocumentID | oai_DiVA_org_uu_74031 15928246 17004765 10_1210_jc_2005_0185 10.1210/jc.2005-0185 |
| Genre | Journal Article Comparative Study |
| GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ J5H KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WHG WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 29K 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ AAYXX ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU CITATION D-I EIHJH FEDTE FYUFA HMCUK HVGLF H~9 IAO IHR INH ITC M1P MBLQV NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 X52 ZGI ZXP IQODW PJZUB PPXIY 3V. CGR CUY CVF ECM EIF NPM VXZ 7QP 7T5 7TM AEHZK H94 K9. 7X8 ADTPV AOWAS DF2 PUEGO |
| ID | FETCH-LOGICAL-c415t-643d02e356a8912f1813764c5bf3c52ecf2008abc224aa52d060fee0622e7d8a3 |
| ISSN | 0021-972X |
| IngestDate | Tue Sep 09 23:36:57 EDT 2025 Mon Sep 08 03:55:00 EDT 2025 Fri Sep 19 20:55:24 EDT 2025 Wed Feb 19 01:41:21 EST 2025 Mon Jul 21 09:15:02 EDT 2025 Tue Jul 01 04:01:10 EDT 2025 Thu Apr 24 23:10:11 EDT 2025 Fri Feb 07 10:35:26 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Endocrinopathy Human Intracranial Nervous system diseases Replacement therapy Hormone therapy Deficiency Somatotropin hormone Metabolism Adenohypophyseal hormone Age of onset Hypophyseal insufficiency Pituitary diseases Database Tumor Adult Craniopharyngioma Pituitary Adenoma Endocrinology Comparative study International |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c415t-643d02e356a8912f1813764c5bf3c52ecf2008abc224aa52d060fee0622e7d8a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| PMID | 15928246 |
| PQID | 3163694088 |
| PQPubID | 2046206 |
| PageCount | 8 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_uu_74031 proquest_miscellaneous_68461096 proquest_journals_3163694088 pubmed_primary_15928246 pascalfrancis_primary_17004765 crossref_primary_10_1210_jc_2005_0185 crossref_citationtrail_10_1210_jc_2005_0185 oup_primary_10_1210_jc_2005-0185 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2005-08-01 |
| PublicationDateYYYYMMDD | 2005-08-01 |
| PublicationDate_xml | – month: 08 year: 2005 text: 2005-08-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Bethesda, MD |
| PublicationPlace_xml | – name: Bethesda, MD – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2005 |
| Publisher | Oxford University Press Endocrine Society |
| Publisher_xml | – name: Oxford University Press – name: Endocrine Society |
| SSID | ssj0014453 |
| Score | 2.0719125 |
| Snippet | Objective: In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by... In epidemiological studies, hypopituitary adults show increased mortality compared with population controls. Patients with hypopituitarism caused by a... |
| SourceID | swepub proquest pubmed pascalfrancis crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4636 |
| SubjectTerms | Adenoma Adenoma - complications Adenoma - mortality Adenoma - surgery Adult Age of Onset Biological and medical sciences Blood Glucose Body Composition Body fat Cardiovascular disease Cardiovascular diseases Cholesterol Comorbidity Coronary artery disease Craniopharyngioma - complications Craniopharyngioma - mortality Craniopharyngioma - surgery Databases, Factual Diabetes mellitus Dyslipidemia Endocrinopathies Epidemiology Fasting Fat-free body mass Female Fractures Fundamental and applied biological sciences. Psychology Glycated Hemoglobin A - metabolism Growth hormones Heart diseases High density lipoprotein Hip Human Growth Hormone - deficiency Human Growth Hormone - therapeutic use Humans Hypopituitarism Hypopituitarism - drug therapy Hypopituitarism - etiology Hypopituitarism - mortality Hypothalamus. Hypophysis. Epiphysis (diseases) Insulin-Like Growth Factor I - metabolism Lipids Lipids - blood Male Medical sciences Metabolic disorders Middle Aged Mortality Neoplasia Non tumoral diseases. Target tissue resistance. Benign neoplasms Patients Pituitary Pituitary Neoplasms - complications Pituitary Neoplasms - mortality Pituitary Neoplasms - surgery Population studies Prevalence Quality of Life Surgery Treatment Outcome Triglycerides Tumors Vertebrates: endocrinology |
| Title | Baseline Characteristics and Response to 2 Years of Growth Hormone (GH) Replacement of Hypopituitary Patients with GH Deficiency due to Adult-Onset Craniopharyngioma in Comparison with Patients with Nonfunctioning Pituitary Adenoma: Data from KIMS (Pfizer International Metabolic Database) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/15928246 https://www.proquest.com/docview/3163694088 https://www.proquest.com/docview/68461096 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-74031 |
| Volume | 90 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZT9tAEN4ClapKVdW7aSmdSlQCRa4Sx2ffUo6YckVVqOiTtb7ACOwo2A_w2F_eGe_6CofavkQoXsaGnW_n8Mw3jK1qoT2weWArto7um8aNPmGup5h9z_R830MfgBqF9w8M50j7fqwfLyz-blQt5Zn3xb--ta_kf3YVv8N9pS7Zf9jZSih-gT_j_uIn7jB-_tUef-NFO3lYvDSfp13-Iapfi9EYavcXanRRtTHCuDs77Troq6bCwRw5lBpAT5wy6mVtgHM1TadxlscZldWNBfuqbIUbOXhMEfNE0bYZ5MUthkTkoRziDbPuBhrAOJ3iQ10lJ3F6wUVvYTXxsJDSlnmQJmRiy_TwuLr1EA9GlECZi02ecdEPs7tT5B-scRRfh7O5tOZ-mKFmE3k3_QKZ6TLdcVZDo8GYUTWHhkmQ4iGa1LRUF1KUpFmkwWTh7BTdiUyWMdfYQosV8PNzpU6B4B9YxSuzKJelmBi6UINUXAFqTLROVXtByebQysboVS1gdl-XZ9MCUUmMWYyQR_srjI6t6QgOUadcWiUxRFWiz2qYGGJ4a7grmiForm6YQozlyRQWNJ1UnykmI7UZxw8O3e2jvT13snU8WWQPVRP9TwosdnarN3GaJplc5XPL5hHq_GrKbrl1olX0yZRf4uZFYkDMbRHcHD1v4dJNnrGnMhaDoQDWc7YQJi_Yo31ZbfLywacSXzCHL0DdgBJfkKWgQoEvSCMQ-AKJL1gbOevQwBYtaWELShwA4QBGDtTYAsQWiW9gC25gC-IEamwJKW2ZbWxBhS2Q2PoKBBQgZAEhC9YErqCFK6hwBSWu1l-xo-2tyYajyJEqio-eeqagsgQ9NRzoBrfsvhqhf48ehubrXjTwdTX0I6qH4p6Pnj3nuhr0jF4Uhj1DVUMzsPjgNVtK8L_3lgEGKpzI__qm5Wk-N20UqfqRFXiaFfk9v8O6pUa4vpw3QGNvzl3KO6D-uGc-DcHVXdKfDvtcrZ4Knp071gEq111LFLFkpaV59WIa5WEauGC5VEVXnjaX7gADU8PW0OnqsI_VZbS19AKVJ2GaX7qGVUynMDrsjVDgWrRuq5aq4ZVVodHVFaLv34x_Dt10duLmuWtq6Ea9u_8J3rPH9dmyzJayWR5-wNgn81YKcP4BP8NmXw |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baseline+Characteristics+and+Response+to+2+Years+of+Growth+Hormone+%28GH%29+Replacement+of+Hypopituitary+Patients+with+GH+Deficiency+due+to+Adult-Onset+Craniopharyngioma+in+Comparison+with+Patients+with+Nonfunctioning+Pituitary+Adenoma%3A+Data+from+KIMS+%28Pfizer+International+Metabolic+Database%29&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Verhelst%2C+Johan&rft.au=Kendall-Taylor%2C+Pat&rft.au=Erfurth%2C+Eva+Marie&rft.au=Price%2C+David+Anthony&rft.date=2005-08-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=90&rft.issue=8&rft.spage=4636&rft.epage=4643&rft_id=info:doi/10.1210%2Fjc.2005-0185&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |